18 November 2014

CHICAGO, November 18, 2014 — LoneStar Heart, Inc. today presented the primary six month results of its multicenter, randomized clinical trial of Algisyl-LVR® providing evidence that the cardiac hydrogel implant can prevent or reverse the symptoms of moderate to severe heart failure in patients with a dilated and weakened left ventricle. The improvement in clinical status and quality of life of the patients was consistent with reported data that demonstrates the cardiac hydrogel works by improving the failing heart’s structure and function. Read more